Wook-Je Cho (L), CEO of Yuhan Corporation, and Anna Jo, CEO of J INTS BIO
May 31, 2023 03:17 PM EDT
Deals
Pharma

Yuhan Cor­po­ra­tion to pay $325M to in-li­cense pre­clin­i­cal HER2 can­di­date

Paul Schloesser

Associate Editor

Yuhan Cor­po­ra­tion said Tues­day that it is pay­ing up to $325 mil­lion to fel­low South Ko­re­an biotech J INTS Bio to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Chi­na’s biotech mar­ket is stag­ing a come­back that US biotech can on­ly wish for

With aims to be­come a 'gen­er­a­tional biotech,' Zealand Phar­ma hires Lil­ly vet­er­an as sci­ence chief

Genen­tech vet launch­es ADC start­up with $20M

Bris­tol My­er­s' schiz­o­phre­nia drug fails Phase 3 tri­al for ad­junc­tive treat­ment

As­cle­tis posts puz­zling Phase 1 up­date on obe­si­ty pill

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times